{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:08:31Z","timestamp":1769915311844,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13318-023-00850-8","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:02:05Z","timestamp":1694419325000},"page":"647-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population Pharmacokinetic Analysis of Vancomycin in Patients with Solid or Hematological Malignancy in Relation to the Quick Sequential Organ Failure Assessment Scores"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-0982","authenticated-orcid":false,"given":"Yasumasa","family":"Tsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Echizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"850_CR1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77:835\u201364. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036.","journal-title":"Am J Health Syst Pharm"},{"key":"850_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","volume":"20","author":"M Yasuhara","year":"1998","unstructured":"Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20:139\u201348. https:\/\/doi.org\/10.1097\/00007691-199804000-00003.","journal-title":"Ther Drug Monit"},{"key":"850_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2710.2008.01016.x","volume":"34","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with Gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009;34:473\u201383. https:\/\/doi.org\/10.1111\/j.1365-2710.2008.01016.x.","journal-title":"J Clin Pharm Ther"},{"key":"850_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"850_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","volume":"59","author":"A Aljutayli","year":"2020","unstructured":"Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin Part I. In adults. Clin Pharmacokinet. 2020;59:671\u201398. https:\/\/doi.org\/10.1007\/s40262-020-00866-2.","journal-title":"Clin Pharmacokinet"},{"key":"850_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1248\/yakushi.130.69","volume":"130","author":"S Sadoh","year":"2010","unstructured":"Sadoh S, Tsuji Y, Tsukamoto K, Tsukamoto K. Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies. Yakugaku Zasshi. 2010;130:69\u201373. https:\/\/doi.org\/10.1248\/yakushi.130.69.","journal-title":"Yakugaku Zasshi"},{"key":"850_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00134-013-2909-9","volume":"39","author":"Y Shimamoto","year":"2013","unstructured":"Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013;39:1247\u201352. https:\/\/doi.org\/10.1007\/s00134-013-2909-9.","journal-title":"Intensive Care Med"},{"key":"850_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1248\/yakushi.14-00214","volume":"135","author":"J Irikuchi","year":"2015","unstructured":"Irikuchi J, Imai T, Yoshida Y, Orii T. Influence of systemic inflammatory response syndrome on the pharmacokinetics of vancomycin. Yakugaku Zasshi. 2015;135:745\u201351. https:\/\/doi.org\/10.1248\/yakushi.14-00214.","journal-title":"Yakugaku Zasshi"},{"key":"850_CR9","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.clinthera.2016.10.009","volume":"38","author":"M Chuma","year":"2016","unstructured":"Chuma M, Makishima M, Imai T, Tochikura N, Sakaue T, Kikuchi N, et al. Duration of systemic inflammatory response syndrome influences serum vancomycin concentration in patients with sepsis. Clin Ther. 2016;38:2598\u2013609. https:\/\/doi.org\/10.1016\/j.clinthera.2016.10.009.","journal-title":"Clin Ther"},{"key":"850_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"key":"850_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.2016.0288","volume":"315","author":"CW Seymour","year":"2016","unstructured":"Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:762\u201374. https:\/\/doi.org\/10.1001\/jama.2016.0288.","journal-title":"JAMA"},{"key":"850_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"850_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire NH, Aspelin P. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012;2:1\u201338.","journal-title":"Kidney Int"},{"key":"850_CR14","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.21037\/tau-20-1048","volume":"9","author":"J He","year":"2020","unstructured":"He J, Yang ZT, Qian X, Zhao B, Mao EQ, Chen EZ, et al. A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance. Transl Androl Urol. 2020;9:2166\u201371. https:\/\/doi.org\/10.21037\/tau-20-1048.","journal-title":"Transl Androl Urol."},{"key":"850_CR15","first-page":"96","volume":"36","author":"M Suzuki","year":"2019","unstructured":"Suzuki M, Kasai H, Sako K. Population pharmacokinetic analysis of vancomycin in adult cancer patients with neutropenia effect. The Jpn J Ther Drug Monit. 2019;36:96\u2013104.","journal-title":"The Jpn J Ther Drug Monit."},{"key":"850_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/875512250101700201","volume":"17","author":"TA Rushing","year":"2016","unstructured":"Rushing TA, Ambrose PJ. Clinical application and evaluation of vancomycin dosing in adults. Journal of Pharmacy Technology. 2016;17:33\u20138. https:\/\/doi.org\/10.1177\/875512250101700201.","journal-title":"Journal of Pharmacy Technology"},{"key":"850_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijantimicag.2016.06.022","volume":"48","author":"AJ Kim","year":"2016","unstructured":"Kim AJ, Lee JY, Choi SA, Shin WG. Comparison of the pharmacokinetics of vancomycin in neurosurgical and non-neurosurgical patients. Int J Antimicrob Agents. 2016;48:381\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.06.022.","journal-title":"Int J Antimicrob Agents"},{"key":"850_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"850_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181\u2013247. https:\/\/doi.org\/10.1007\/s00134-021-06506-y.","journal-title":"Intensive Care Med"},{"key":"850_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/IDR.S121513","volume":"9","author":"W Katip","year":"2016","unstructured":"Katip W, Jaruratanasirikul S, Pattharachayakul S, Wongpoowarak W, Jitsurong A, Lucksiri A. The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock. Infect Drug Resist. 2016;9:253\u201360. https:\/\/doi.org\/10.2147\/IDR.S121513.","journal-title":"Infect Drug Resist."},{"key":"850_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/j.1469-0691.2009.03074.x","volume":"16","author":"J Goncalves-Pereira","year":"2010","unstructured":"Goncalves-Pereira J, Martins A, Povoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect. 2010;16:1258\u201363. https:\/\/doi.org\/10.1111\/j.1469-0691.2009.03074.x.","journal-title":"Clin Microbiol Infect"},{"key":"850_CR22","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/CCM.0000000000002538","volume":"45","author":"HE Wang","year":"2017","unstructured":"Wang HE, Jones AR, Donnelly JP. Revised national estimates of emergency department visits for sepsis in the United States. Crit Care Med. 2017;45:1443\u20139. https:\/\/doi.org\/10.1097\/CCM.0000000000002538.","journal-title":"Crit Care Med"},{"key":"850_CR23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s13318-019-00564-w","volume":"44","author":"H Nakayama","year":"2019","unstructured":"Nakayama H, Suzuki M, Kato T, Echizen H. Vancomycin pharmacokinetics in patients with advanced cancer near end of life. Eur J Drug Metab Pharmacokinet. 2019;44:837\u201343. https:\/\/doi.org\/10.1007\/s13318-019-00564-w.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"850_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijantimicag.2011.12.011","volume":"39","author":"JP Baptista","year":"2012","unstructured":"Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents. 2012;39:420\u20133. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.12.011.","journal-title":"Int J Antimicrob Agents"},{"key":"850_CR25","first-page":"357","volume":"53","author":"H Teramachi","year":"2005","unstructured":"Teramachi H, Matsushita R, Tsuji A. Influence of malignancy on the pharmacokinetics of vancomycin hydrochloride in Japanese MRSA patients after dosage adjustment with the Bayesian method. Jpn J Chemother. 2005;53:357\u201363.","journal-title":"Jpn J Chemother."},{"key":"850_CR26","first-page":"1","volume":"30","author":"S Aoyama","year":"2013","unstructured":"Aoyama S, Teramachi H, Miyazato T. Investigation for factors affecting clearance of vancomycin. The Jpn J Ther Drug Monit. 2013;30:1\u20135.","journal-title":"The Jpn J Ther Drug Monit."},{"key":"850_CR27","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/phar.2475","volume":"40","author":"S Alqahtani","year":"2020","unstructured":"Alqahtani S, Almatrafi A, Bin Aydan N, Alqahtani M, Alzamil F, Alsultan A, et al. Optimization of vancomycin dosing regimen in cancer patients using pharmacokinetic\/pharmacodynamic modeling. Pharmacotherapy. 2020;40:1192\u2013200. https:\/\/doi.org\/10.1002\/phar.2475.","journal-title":"Pharmacotherapy"}],"updated-by":[{"DOI":"10.1007\/s13318-024-00890-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000}}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00850-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00850-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00850-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T04:50:21Z","timestamp":1710737421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00850-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00850-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13318-024-00890-8","asserted-by":"object"}]},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"7 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13318-024-00890-8","URL":"https:\/\/doi.org\/10.1007\/s13318-024-00890-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest directly relevant to the content of the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All software used in the present study is commercially available and the necessary information was given in the text.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study protocol was approved by the Research Ethics Committee of St. Luke\u2019s International Hospital (approval number 16-074).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent from participating patients was waived because all blood samples for TDM were obtained for therapeutic purposes as well as other medical procedures under the comprehensive agreement of patients. The opt-out statement for the present study was disclosed to the hospital\u2019s public statement board.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The original code of the population pharmacokinetic\u00a0model may be available upon a reasonable request from the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"YT, MT, and FW designed the research. YT collected the data. YT and MT performed the data analysis and the pharmacokinetic analysis. YT wrote the draft manuscript. YT, MT, FW, KG, and HE substantially contributed to revising the manuscript drafts. All authors approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}}]}}